Indian pharmaceutical major Cipla announced on Friday that it has been granted approval by the Drugs Controller General of India (DCGI) to sell antiviral drug favipiravir to treat mild to moderate COVID-19 patients. Cipla will sell the drug under the brand name Ciplenza at ₹68 per tablet. Ciplenza has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology.